article thumbnail

Article FDA Thank You Following a 2018 draft framework, FDA unveils long-awaited PDURS draft guidance

Agency IQ

Following a 2018 draft framework, FDA unveils long-awaited PDURS draft guidance A long-awaited draft guidance on Prescription Drug Use-Related Software (PDURS) outlines when information from digital health tools could be represented on prescription drug labeling. See AgencyIQ’s full analysis of the 2018 framework, and industry response, here.]

FDA 40
article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

What is likely to be the cumulative effect on innovation of the different losses in exclusivity, also given the forthcoming Patent Package which could link the review’s rules on product shortages to EU-wide compulsory licensing? She also does not believe that the problems with Europe’s medicines can be solved with regulation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hemogenyx Pharmaceuticals PLC Announces Update on CDX Antibody Development

The Pharma Data

On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation No 596/2014 until the release of this announcement.

article thumbnail

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

The Pharma Data

Syndesi’s unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018.

article thumbnail

Article FDA Thank You CDER’s latest novel drug approvals report shows how the pandemic is still affecting some drug approvals

Agency IQ

BY AMANDA CONTI | JAN 10, 2024 9:29 PM CST Quick background: Goal dates under the Prescription Drug User Fee Act (PDUFA) The FDA collects user fees as part of an essential bargain between regulators and industry. In fact, CDER received a perfect 100% for meeting PDUFA dates for novel drugs in 2013, 2017, 2018 and 2020.

FDA 40
article thumbnail

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

The Pharma Data

On December 17, 2018, Toripalimab obtained a conditional approval from the National Medical Products Administration (the “NMPA”) for the second-line treatment of unresectable or metastatic melanoma. The FTD is designed to make important new drugs accessible to patients faster.

FDA 52
article thumbnail

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

The Pharma Data

. “ This marks our second strategic agreement with Asieris, a well-run and well-capitalized company that is executing ahead of plan on the clinical development of Cevira ®, which we licensed to them in July 2019. 75% of all bladder cancer cases occur in men.